Proteolytic activity inSerratia marcescens clinical isolates

R. Coria-Jiménez; C. Zárate-Aquino; O. Ponce-Ponce

doi:10.1007/bf02931050

journal article May 01, 2004

Proteolytic activity inSerratia marcescens clinical isolates

R. Coria-Jiménez C. Zárate-Aquino O. Ponce-Ponce

Folia Microbiologica Vol. 49 No. 3 pp. 321-326 · Springer Science and Business Media LLC

View at Publisher Save 10.1007/bf02931050

Topics

No keywords indexed for this article. Browse by subject →

References

31

[1]

Abbot S.:Klebsiella, Enterobacter, Citrobacter, andSerratia, pp. 475–482 in P.R. Murray, E.J. Baron, M.A. Pfaller, F.C. Tenover, R.H. Yolken (Eds):Manual of Clinical Microbiology. ASM Press, Washington (DC) 1999.

[2]

Aucken H.M., Pitt T.L.: Antibiotic resistance and putative virulence factors ofSerratia marcescens with respect to O and K serotypes.J.Med.Microbiol. 47, 1195–1113 (1998).

[3]

Bar-Ness R., Rosenberg M.: Putative role of a 70-kDa outer-surface protein in promoting cell-surface hydrophobicity ofSerratia marcescens RZ.J.Gen.Microbiol. 135, 2277–2281 (1989).

[4]

Bogyiová E., Siegfried L., Kmeťová M., Šándorčínová Z., Liptáková A., Biroš E.: Occurrence and genetic association of selected virulence factors in clinicalEscherichia coli isolates.Folia Microbiol. 47, 73–77 (2002). 10.1007/bf02818569

[5]

Bollman R., Halle E., Sokolowska-Kohler W., Grauel E.L., Bucholz P., Klare I., Tshapé H., Witte W.: Nosocomial infections due toSerratia marcescens, clinical findings, antibiotic susceptibility patterns and fine typing.Infection 17, 294–300 (1989). 10.1007/bf01650711

[6]

Bromke B.J., Venuti E.: A basal-defined medium for the study of proteolytic activity ofSerratia marcescens.Can.J.Microbiol. 45, 88–91 (1999). 10.1139/w98-123

[7]

Carbonell G.V., Fonseca B.A.L., Figuereido L.T.M., Darini A.L.C., Yanaguita R.M.: Culture conditions affect cytotoxin production bySerratia marcescens.FEMS Immunol.Med.Microbiol. 16, 299–307 (1996). 10.1111/j.1574-695x.1996.tb00149.x

[8]

Carbonell G.V., Vidotto M.C.: Virulence factors inSerratia marcescens: cell-bound hemolysin and aerobactin.Braz.J.Med.Biol.Res. 25, 1–8 (1992).

[9]

Coria-Jiménez R., Ortiz-Torres C.: Aminoglycoside resistance ofSerratia marcescens strains of clinical origin.Epidemiol.Infect. 112, 125–131 (1994). 10.1017/s0950268800057484

[10]

Coria-Jiménez R., Romero-Olvera J., Celis-Cruz C.: Superficial hydrophobicity inSerratia marcescens strains of clinical origin.Res.Microbiol. 149, 27–29 (1998). 10.1016/s0923-2508(97)83620-0

[11]

Dworniczek E., Kuzko K., Mróz E., Wojciech L., Adamski R., Sobieszczańska B., Seniuk A.: Virulence factors andin vitro adherence ofEnterococcus strains to urinary catheters.Folia Microbiol. 48, 671–678 (2003). 10.1007/bf02993477

[12]

Farmer J.J.:Enterobacteriaceae: introduction and identification, pp. 442–458 in P.R. Murray, E.J. Baron, M.A. Pfaller, F.C. Tenover, R.H. Yolken (Eds):Manual of Clinical Microbiology, ASM Press, Washington (DC) 1999.

[13]

Franiczek R., Sobieszczańska B., Grabowski M., Mowszet K., Pytrus T.: Occurrence of extended-spectrum β-lactamases amongEscherichia coli isolates from hospitalized and healthy children.Folia Microbiol. 48, 243–248 (2003). 10.1007/bf02930963

[14]

Serratia marcescens

A. HEJAZI, F. R. FALKINER

Journal of Medical Microbiology 1997 10.1099/00222615-46-11-903

[15]

Hernández-Delgadillo R., Ruiz-Cruz J.J.: Actividad proteolítica libre deSerratia marcescens II. Cinética de producción y mecanismo de inducción.Rev.Lat-Amer.Microbiol. 36, 93–100 (1994).

[16]

Hertle R., Hilger M., Weingardt-Kocher S., Walev I.: Cytotoxic action ofSerratia marcescens hemolysin on human epithelial cells.Infect.Immun. 67, 817–825 (1999). 10.1128/iai.67.2.817-825.1999

[17]

Kamata R., Yamamoto T., Matsumoto K., Maeda H.: A serratial protease causes vascular permeability reaction by activation of the Hageman factor-dependent pathway in Guinea pigs.Infect.Immun. 48, 747–753 (1985). 10.1128/iai.48.3.747-753.1985

[18]

Kim N., Kim S.I.: Characterization and primary specificity of an extracellular metalloproteinase fromSerratia marcescens.Can.J.Microbiol. 40, 120–126 (1994). 10.1139/m94-019

[19]

CRYSTALLINE SOYBEAN TRYPSIN INHIBITOR

M. Kunitz

Journal of General Physiology 1947 10.1085/jgp.30.4.291

[20]

Lockwood B.C., North M.J., Scott K.I., Brenner A.F., Coomles G.H.: The use of a highly sensitive electrophoretic method to compare the proteinases of trichomonads.Mol.Biochem.Parasitol. 24, 89–95 (1987). 10.1016/0166-6851(87)90119-8

[21]

Lyerly D., Gray L., Kreger A.: Characterization of rabbit corneal damage produced bySerratia keratitis andSerratia protease.Infect.Immun. 31, 927–932 (1981). 10.1128/iai.33.3.927-932.1981

[22]

Lyerly D., Kreger A.: Importance ofSerratia proteases in the pathogenesis of experimentalSerratia marcescens pneumoniae.Infect.Immun. 40, 113–119 (1983). 10.1128/iai.40.1.113-119.1983

[23]

Majtánová L., Majtán V.: Postantibiotic effects of gentamicin and netilmicin onSerratia marcescens: effects on hydrophobicity and motility.Folia Microbiol. 45, 45–50 (2000). 10.1007/bf02817449

[24]

Matsumoto K., Maeda H., Takata T., Okamura R.: Purification and characterization of four proteases from clinical isolateSerratia marcescens KUMS 3958.J.Bacteriol. 157, 225–232 (1984). 10.1128/jb.157.1.225-232.1984

[25]

Molla A., Matsumoto A., Oyamada T., Katsuli T., Maeda H.: Degradation of protease inhibitors, immunoglobulins, and other serum proteins bySerratia protease and its toxicity to fibroblasts in culture.Infect.Immun. 53, 522–529 (1986). 10.1128/iai.53.3.522-529.1986

[26]

Molla A., Kagimoto T., Maeda H.: Cleavage of immunoglobulin G (IgG) and IgA around the hinge region by proteases fromSerratia marcescens.Infect.Immun. 56, 916–920 (1988). 10.1128/iai.56.4.916-920.1988

[27]

Montaner B., Navarro S., Pique M., Vilaseca M., Martinell M., Giralt E., Gil J., Perez-Tomas R.: Prodigiosin from the supernatant ofSerratia marcescens induces apoptosis in hematopoietic cancer cell lines.Brit.J.Pharmacol. 131, 585–593 (2000). 10.1038/sj.bjp.0703614

[28]

Poole K., Braun B.: Iron regulation ofSerratta marcescens hemolysin gene expression.Infect Immun. 56, 2967–2971 (1998). 10.1128/iai.56.11.2967-2971.1988

[29]

Reed L.J., Muench I.I.: A simple method for estimating fifty per cent endpoints.Amer.J.Hyg. 27, 493–497 (1938).

[30]

Schefler W.C.:Bioestadistica. Fondo Educativo Interamericano, México 1981.

[31]

Yu V.L.:Serratia marcescens. Historical perspective and clinical review.New Engl.J.Med. 300, 887–893 (1979). 10.1056/nejm197904193001604

Metrics

2

Citations

31

References

Details

Published: May 01, 2004
Vol/Issue: 49(3)
Pages: 321-326
License: View

Authors

Cite This Article

R. Coria-Jiménez, C. Zárate-Aquino, O. Ponce-Ponce (2004). Proteolytic activity inSerratia marcescens clinical isolates. Folia Microbiologica, 49(3), 321-326. https://doi.org/10.1007/bf02931050

Proteolytic activity inSerratia marcescens clinical isolates

You May Also Like